Idylla EGFR Mutation Assay
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Assay to their core oncology menu, that now covers most known and used oncology biomarkers.
19Feb
18Feb
ZytoVision FISH Probes for Lung Cancer
ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.
24Jan
Invivoscribe LymphoTrack Dx IVD Assays now available
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
12Dec
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.
On the 3rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.
28Sep
Asuragen: FragileX
The AmplideX® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.
27Sep
Asuragen: C9orf72
The AmplideX® C9orf72 Kit is a tool for the reliable amplification of the hexanucleotide CG repeat in the C9orf72 gene associated with amyotrophic lateral sclerosis and frontotemporal dementia.
18Sep
New Idylla NRAS Mutation Test (CE-IVD)
- Directly on 1 FFPE tissue section
- Detecting 18 relevant mutations
18Sep
Launch of the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only)
Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
18Sep
Idylla ctBRAF Mutation Assay (Research Use Only)
A revolution in liquid biopsy cancer research.